Literature DB >> 3965690

Imipramine and desipramine disposition in the elderly.

D R Abernethy, D J Greenblatt, R I Shader.   

Abstract

Forty-six healthy male and female volunteers aged 21 to 88 received single 12.5-mg i.v. doses of imipramine, and 35 of these people received single 50-mg p.o. imipramine doses on a different occasion. Thirty-five similar volunteers received single 50-mg p.o. desipramine doses. Among these subjects 25 participated in studies of both imipramine and desipramine. Kinetic variables for the respective drugs were determined from multiple plasma drug concentrations from samples obtained during 96 hr after the dosage. Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution. After p.o. imipramine doses time to peak imipramine concentration was shorter in elderly females (2.1 vs. 4.8 hr; P less than .005) but no different in males. Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01). Comparison of p.o. and i.v. imipramine doses indicated no difference in absolute bioavailability between the elderly and young of either sex. In contrast, after p.o. desipramine more limited age-related changes were noted. Desipramine half-life was slightly prolonged in elderly males (30.8 vs. 21.2 hr; P less than .05) apparently related to a nonsignificant decrease in p.o. clearance.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965690

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  36 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Adverse effects of antidepressants in the elderly.

Authors:  L Nolan; K O'Malley
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

Review 3.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 4.  Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.

Authors:  Richard D Boyce; Steven M Handler; Jordan F Karp; Joseph T Hanlon
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-27

5.  [Expanding therapeutic reference ranges using dose-related reference ranges].

Authors:  E Haen; C Greiner; W Bader; M Wittmann
Journal:  Nervenarzt       Date:  2008-05       Impact factor: 1.214

Review 6.  Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications.

Authors:  A Hämmerlein; H Derendorf; D T Lowenthal
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

7.  Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage.

Authors:  R J Flanagan; A Johnston; A S White; P Crome
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

8.  Predicted metabolic drug clearance with increasing adult age.

Authors:  Thomas M Polasek; Farhaan Patel; Berit P Jensen; Michael J Sorich; Michael D Wiese; Matthew P Doogue
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

9.  Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly.

Authors:  K W Woodhouse; H A Wynne
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 10.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.